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Oxythiamine (OT), an analogue of anti-metabolite, can suppress the nonoxidative synthesis of ribose and induce
cell apoptosis by causing a G1 phase arrest in vitro and in vivo. However, the molecular mechanism remains unclear
yet. In the present study, a quantitative proteomic analysis using the modified SILAC method (mSILAC) was
performed to determine the effect of metabolic inhibition on dynamic changes of protein expression in MIA PaCa-2
cancer cells treated with OT at various doses (0 μM, 5 μM, 50 μM and 500 μM) and time points (0 h, 12 h and 48 h).
A total of 52 differential proteins in MIA PaCa-2 cells treated with OT were identified, including 14 phosphorylated
proteins. Based on the dynamic expression pattern, these proteins were categorized in three clusters, straight
down-regulation (cluster 1, 37% of total proteins), upright “V” shape expression pattern (cluster 2, 47.8% total), and
downright “V” shape pattern (cluster 3, 15.2% total). Among them, Annexin A1 expression was significantly down-
regulated by OT treatment in time-dependent manner, while no change of this protein was observed in OT dose-
dependent fashion. Pathway analysis suggested that inhibition of transketolase resulted in changes of multiple
cellular signaling pathways associated with cell apoptosis. The temporal expression patterns of proteins revealed
that OT altered dynamics of protein expression in time-dependent fashion by suppressing phosphor kinase
expression, resulting in cancer cell apoptosis. Results from this study suggest that interference of single metabolic
enzyme activity altered multiple cellular signaling pathways.
Keywords: Quantitative proteomics, Pancreas cancer, 15 N stable isotope, Phosphorylation, Turnover rate, Metabolic
inhibitor, Metabolic therapy, Transketolase, OxythiamineIntroduction
It has been known for decades that most tumor cells
and tissues enhanced glucose metabolism by glycolysis
[1,2]. Although its causal relationship with cancer cell
proliferation is still unclear, the phenomenon has been
developed a reliable technique for detecting and classify-
ing tumors by fluorodeoxyglucose positron emission
tomography (FDG-PET) [3,4]. In recent years, this meta-
bolic alteration of malignant cells has been observed in* Correspondence: wqdmu@yahoo.com.cn; gxiao@creighton.edu
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reproduction in any medium, provided the ormultiple cancer cells, and it has become an important
aspect for design of anticancer drugs that inhibits gly-
colysis and other relevant metabolic processes. Several
small molecules, including 2-deoxyglucose, lonidamine,
3-bromopyruvate, imatinib and oxythiamine (OT), have
shown the effectiveness in anticancer activity in vitro
and in vivo [5-16]. They are currently in the clinical and
pre-clinical phase. Some other compounds also exhibit
potential anticancer activity by modulating glucose me-
tabolism [16].
OT is a thiamine antagonist and inhibits transketolase
(TK) which is an enzyme of the pentose phosphate path-
way in animals. As transketolase reaction plays a vital
role of the pentose phosphate pathway, inhibition of
transketolase will suppress the pentose phosphate path-
way and interrupt the synthesis of these importanttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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terial, RNA and DNA in cancer cells. OT can suppress
the nonoxidative synthesis of ribose and cause cell apop-
tosis by inducing a G1 phase arrest in vitro and in vivo
[14,15,17,18]. Although the exactly molecular mechanism
is not clear, it has been accepted that the decreased bio-
logical macromolecular synthesis can inhibit cell prolifera-
tion and induces cell apoptosis. Therefore, these features
of metabolism are actually used for cancer therapeutic ap-
proach known as “metabolic therapy” [19,20].
In the present study, a dynamic proteomic method
was adapted to analyze the effects of antimetabolite OT
on dynamic changes of protein expression in pancreatic
cancer cells, thus to understand the molecular mechan-
ism underlying antimetabolite interference.
Materials and methods
Chemicals and regents
15 N enriched algal amino acid mixture (15 N enrich-
ment, 98%) was purchased from Cambridge Isotope La-
boratory Inc. (Andover, MA). Fetal bovine serum (FBS)
was purchased from Irvine Scientific (Santa Ana, CA).
Dulbecco’s modified Eagles’s medium and antimycotic
were from Gibco (Calsbad, CA). Sequence grade trypsin
solution was from Promega (Madison, WI).
Acetonitrile was purchased from Thermo Fisher Scien-
tific (Rockford, IL). Materials employed for gel electrophor-
esis were purchased from BioRad. Water was prepared
using a Milli-Q system (Millipore, Bedford, MA). Other
chemicals employed were purchased from Sigma (St. Louis,
MO). This project was approved by Creighton University
Institutional Review Board.
In vitro cytotoxic activity
The cell cytotoxicity of OT against the MIA PaCa-2 cells
was determined by MTT assay [21,22]. The cells at expo-
nential phase were dispensed in 96-well plates at a density
of 1 × 104 cells per well. The cells were stimulated with
different concentrations of OT for 2 days. The cells were
then incubated in 20 μl MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl tetrazolium bromide) (Sigma, USA) in
growth medium at 37°C for 4 h lysed in 100 μl of dimethyl
sulfoxide (Sigma, USA) for 10 min. The absorbance in
each well was measured at 490 nm by an ELx800 Absorb-
ance Microplate Reader (Biotek, CA). The cell viability
and IC50 value were calculated by the following equations:
cell viability =mean optical density of experimental group/
mean of the control × 100%; IC50 value = concentration of
OT at 50% cell viability.
Cell culture
Human pancreatic carcinoma cell line MIA PaCa-2 was
maintained in MEM supplemented with 10% fetal bovine
serum and 1% antibiotic antimycotic at 37°C in 5% CO2until 80% confluence when the experiment started
[23,24]. Experiments were set up in two groups: dose-
and time-dependent groups. For the dose-dependent
group, the cells were stimulated with 5, 50 and 500 μM
OT for 48 hours, respectively. The unstimulated cells
were considered as control. For the time-dependent
group, the cells were stimulated with 50 μM OT in
MEM containing natural amino acids or 50% of 15 N
algal amino acid mixture (15 N enrichment, 98%) for 12
and 48 h. The unstimulated cells were considered as the
zero time point. Each treatment was repeated four times
with 10 mL/flask. The cell pellets were then collected
for further analysis.
Protein sample preparation
The cell pellets were immediately washed three times with
ice-cold PBS. Cells were harvested in 2-DE lysis buffer with
protease inhibitor set III and phosphatase inhibitor set II
(Calbiochem, La Jolla, CA). The suspension was sonicated
at 100 Watt for 3 × 5 s and centrifuged at 20,000 × g for
30 min. Protein concentration was measured by Bradford
assay using bovine serum albumin as the standard. The
samples were stored at −80°C until analysis.
Two-Dimensional Gel Electrophoresis (2-DE)
Two-DE was performed as previously described [23,24].
Briefly, five hundred micrograms of proteins were mixed
with a rehydration solution (Bio-Rad, Hercules, CA)
containing 7 M urea, 2 M thiourea, 4% CHAPS, 50 mM
DTT, 0.2% biolyte 3–10, 0.1% biolyte 4–6, and 0.1% biolyte
5–8 and a trace of bromophenol blue to a total volume of
300 μL. The mixtures were pipetted into IPG strip holder
channels. After 14 h of rehydration, the strips, pH 3–10
NL, were transferred to the isoelectric focusing (IEF)
holders (Bio-Rad, Hercules, CA). Prefocusing and focusing
were performed on the IPGphor platfor (Bio-Rad,
Hercules, CA) (500 V hold 2.5 h, linear 500–1000 V in-
crease 1 h, 1000 V hold 1 h, linear 1000-8000 V increase
1.5 h, and 8000 V hold 60,000 KV h). Following IEF separ-
ation, the gel strips were equilibrated twice for 15 min
each with equilibration buffer I and II (37.5 mM Tris-Cl,
pH 8.8, 20% glycerol, 2% SDS, 6 M urea, with 2% DTT in
buffer I and 2.5% iodoacetamide in buffer II, respectively).
The equilibrated gel strips were then placed onto 8-16%
Tris–HCl gel, and sealed with 0.5% agarose in a Protean
Plus Dodeca cell (Bio-Rad, Hercules, CA) until the
bromophenol blue reached the bottom of the gels.
After 2-DE, the gels were stained with Pro-Q Diamond
[25,26]. Then the gels were stained using SYPRO-Ruby
(Molecular Probes, Eugene, OR) or visualized with the
Coomassie Brilliant Blue R-250 (Merck, Germany) over-
night at room temperature. Following 2-DE and protein
staining, stained gels were scanned with a Pharox FX
molecular imager (Bio-Rad) with a 532 nm laser
Wang et al. Experimental Hematology & Oncology 2013, 2:18 Page 3 of 14
http://www.ehoonline.org/content/2/1/18excitation and a 580 nm band-pass emission filter. Spot
detection, quantification and matching were identified
using PDQuest 8.0 software (Bio-Rad). The intensity of
each protein spot was normalized to the entire gel inten-
sity of all spots detected. Quantitative analysis was
performed using the Student’s t-test. The confidence
level was 95%. Only those proteins of intensity differ-
ence > 2-fold change were selected for MALDI-TOF
/TOF MS.
In-gel Trypsin digestion
Protein spots of interest were excised from the gels and
in-gel digested with trypsin as previously described [27].
Briefly, gel pieces were destained with 100 mM ammo-
nium bicarbonate in 30% ACN and dried in a vacuum
centrifuge. Ten ng of modified trypsin (Promega,
Madison, WI) in 25 mM ammonium bicarbonate was
added, followed by incubation 20 h at 37°C. The super-
natant was collected, and then the peptides were further
extracted three times from the gel pieces with 0.1%
trifluoroacetic acid (TFA), 60% ACN with vortexing for
45 min at room temperature. Peptides extracts were
vacuum-dried.
MALDI-TOF-MS
For mass spectrometric analysis, the peptides extracts
were brought up in 10 μL of 0.1% TFA and cleaned
using C18 ZipTip (Millippore, MA). Typically, 2 μL of a-
cyano-4-hydroxycinnamic acid (HCCA) matrix in 50%
ACN/0.1% TFA was used to elute peptide onto the
ground steel plate (Bruker, Germany). The internal
standard from Bruker Bruker (MH1: angiotensin II,
1046.5420 Da; angiotensin I, 1296.6853 Da; substance P,
1347.7361 Da; bombesin, 1619.823 Da; ACTH clip 18–
39, 2465.199 Da) were used for mass scale calibration.
The resulting peptides were extracted and analyzed by
MALDI TOF/TOF mass spectrometer (Ultraflex III,
Bruker, Germany) in the reflector mode and for se-
quence analysis in the “lift” mode.
Protein identification and spectral data analysis
The MS/MS spectrum from MALDI measurements
were then searched against the Mus musculus subset
(16235 sequences) of UniProt KB/Swiss-Prot/TrEMBL
database (database version 57.15; 515203 sequences)
using the Mascot v 2.2 search program (Matrix Science,
London, United Kingdom) (www.matrixscience.com).
Search parameters for the database search with Mascot
were set as follows: enzyme, trypsin; allowance of up to
one missed cleavage peptide; fixed modification param-
eter, carbamidomethylation (C); variable modification
parameters, oxidation (at Met); mass tolerance for pre-
cursor ions was ±1.2 Da; mass tolerance for fragment
ions, ±0.6 Da.Mascot scores of proteins or peptides were used for
protein identification (p < 0.05). In the case of peptides
matching to multiple members of a protein family, the
positive identified protein was selected based on both
the highest score and the highest number of matching
peptides. These peaks were externally calibrated with
peptide standards from Bruker (MH1: angiotensin II,
1046.5420 Da; angiotensin I, 1296.6853 Da; substance P,
1347.7361 Da; bombesin, 1619.823 Da; ACTH clip 18–
39, 2465.199 Da).
The synthesis rates of the differential proteins were calcu-
lated according to our in-house algorithms [24,25]. One-
way ANOVA with the Tukey’s adjustment was used for
multiple comparisons in SPSS 13.0 (SPSS Inc., Chicago, IL).
Pathway analysis
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems,
Inc., Redwood City, CA, www.ingenuity.com) was used
for pathway, network and functional analyses of differen-
tial proteins in the present study.
K-means clustering
Protein ratios were transformed to the log scale (base 2) be-
fore clustering [28]. The Cluster 3.0 freeware software pack-
age was used for clustering analysis (http://bonsai.hgc.jp/
~mdehoon/software/cluster/software.htm). Repeated (10–
100) K-means clustering of proteins was based on Pearson
correlation coefficient of their expression profiles [29].
Western blotting analysis
Western blotting analysis was performed as described
previously [29]. Briefly, after SDS-PAGE separation, pro-
teins were then transferred to PVDF membranes
(Millipore, CA) according to the manufacture’s protocol,
and antibody labeling was visualized using ECL reagent
(Pierce Biotech Inc., Rockford, IL). Western blot score
was a fraction of β-actin or β-tubulin, and measured in
Quantity One (Bio-Rad).
To examine whether Annexin A1 is expressed in pan-
creatic cancer, we separately tested a set of serum sam-
ples from patients (pancreatic tumor; pT2/pT3) and
healthy volunteer subjects with age-matched. The pa-
tient serum samples (n = 7) and the healthy volunteer
blood samples (n = 12) were collected by City of Hope
National Medical Center and NCI-designated Cancer
Center (Duarte, CA) with proper informed consent
according to a protocol approved by the Institute Review
Board. All samples used in this study were further ap-
proved by the Institutional Review Board at Creighton
University. The blood samples in BD VacutainerW Blood
Collection Tubes (BD Ventures, L.L.C., NJ) were frac-
tionated by centrifuging at 1,000 × g for 10 min. The
serum samples were immediately divided into aliquots
and frozen at −80°C. The mean (±SD) age for the tumor
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teer group, 60.3 (±5.4) years. We measured serum levels
of Annexin A1 by using Western blotting analysis. All
the experiments were performed in triplicates.
Results
Oxythiamine caused protein expression in a dose-dependent
manner
Using MTT assay, we determined the toxicity of OT to
MIA PaCa-2 cells and found that the IC50 of OT for
MIA PaCa-2 is 14.95 μM (Additional file 1: Figure S1).
To study whether OT caused protein expression in a
dose-dependent fashion, MIA PaCa-2 cells were treated
with the stepwise concentrations of OT (0 μM, 5 μM,
50 μM and 500 μM). Protein expression in MIA PaCa-2
cells was profiled using two-dimensional gel electrophor-
esis (2DE) (Figure 1A). From Figure 1A, we found that
OT altered protein expression in a dose dependent man-
ner. The differentially expressed proteins were selected
using criterion of > 2-fold difference among groups with
statistical significance (p < 0.05), and led to identification
of eighteen proteins (Table 1). Among them, fourteen
proteins were suppressed significantly, and four were
induced remarkably, by OT treatment. Interestingly,
heat shock cognate 71 kDa protein was detected and
identified from two adjacent spots in the gel (spotsFigure 1 Dose-dependent analysis of the MIA PaCa-2 cells to oxythiam
PaCa-2-2 cells treated with oxythiamine (0 μM, 5 μM, 50 μM, and 500 μM).
intensities of four different concentrations of oxythiamine were calculated,
significance (p < 0.05) were selected after these 2D gels were stained by SY
and 14-3-3 protein beta/alpha) for dose–dependent group. Western blot sc
with the 2-DE analyses.#2 and #3 in Figure 1A), suggesting that this protein
may be underwent post-translational modification by
OT treatment.
To further verify the expression patterns of these pro-
teins in MIA cells, we selected alpha-enolase and 14-3-3
protein beta/alpha to examine protein expression by
Western blot (Figure 1B). The level of alpha-enolase was
increased by OT treatment, while expression of 14-3-3
protein beta/alpha was suppressed by OT at a stratified
dose (Figure 1C). The results were in agreement with
the 2-DE analyses.Oxythiamine altered dynamics of protein expression in
MIA PaCa-2 cells
To investigate whether OT treatment caused dynamic
changes of cellular protein expression in MIA PaCa-2
cells, we treated MIA cells with OT at dose of 50 μM in
different time points (0 h, 12 h and 48 h). To detect
functional cellular protein signals in MIA cells in re-
sponse to OT treatment, we used 15 N labeled amino
acids as tracers to culture the cells, and dynamic synthe-
sis rate of total proteins newly synthesized was calcu-
lated [24] (Figure 2A). Clearly, OT caused dynamic
changes of total protein expression in time dependent
fashion. A total of 46 proteins were identified (Table 2).ine. A. Two-DE patterns of whole-cell proteins obtained from MIA
On the basis of PDQuest software analysis, ratios of normalized spot
and spots showing more than 2.0-fold difference with statistical
PRO Ruby. B. The validation of two differential proteins (alpha-enolase
ores are annotated under the bands. The results were well consistent
Table 1 Identified proteins of differential expression of the MIA PaCa-2 cells in the OT-dose dependent group by
MALDI-TOF/TOF MS
Spot No.a Accession numberb Protein name
Ratio of OT-induced differential expressionc
0 5 50 500 (μM)
1 P14625 Endoplasmin 1 0.27 0.33 0.20
2 P11142 Heat shock cognate 71 kDa protein 1 0.41 025 0.19
3 P11142 Heat shock cognate 71 kDa protein 1 3.13 2.58 2.79
4 P13639 Elongation factor 2 1 0.13 0.09 0.21
5 P08238 Heat shock protein HSP 90-beta 1 0.26 0.18 0.14
6 P07237 Protein disulfide-isomerase 1 0.07 0.22 0.09
7 P13489 Ribonuclease inhibitor 1 0.17 0.24 0.19
8 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 1 7.51 11.45 10.96
9 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 1 0.65 0.43 0.38
10 Q15056 Eukaryotic translation initiation factor 4H 1 0.32 0.15 0.27
11 P56537 Eukaryotic translation initiation factor 6 1 0.40 0.24 0.17
12 P09211 Glutathione S-transferase P 1 0.61 0.57 0.26
13 P30086 Phosphatidylethanolamine-binding protein 1 1 0.63 0.29 0.3
14 P62826 GTP-binding nuclear protein Ran 1 0.37 0.42 0.15
15 P60660 Myosin light polypeptide 6 1 0.34 0.49 0.08
16 P51854 Transketolase 1 4.17 3.30 1.85
17 Q6GMP2 Alpha-enolase 1 0.89 2.13 2.29
18 P31946 14-3-3 protein beta/alpha 1 0.76 0.50 0.55
a. The numbers of the identified protein spots are indicated in Figures 1, 2 and 3;
b. Swiss-Prot/TrEMBL primary accession number.
c. The ratio of expression level (intensity on the gel) of each protein spot were calculated based on the control (0 μM OT) group.
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pression patterns of OT-induced proteins were analyzed.
Forty-five proteins identified from forty-six protein spots,
which showed a 2-fold or greater change, revealed three
different profile patterns, straight down-regulation (cluster
1, 37% of total proteins), upright “V-shape” expression pat-
tern (cluster 2, 47.8% total), and downright “V-shape” pat-
tern (cluster 3, 15.2% total) (Figure 2B).
To further verify the expression patterns of these pro-
teins in time dependent manner, four proteins were se-
lected for further analyses by western blot (Figure 2C).
The expression of peroxiredoxin-6 and annexin A1 in
cluster 1 were decreased upon the OT treatment. Calreti-
culin in cluster 3 was increased significantly at the 12 h
time point, but significantly decreased to its basal level at
the 48 h time point. Heterogeneous nuclear ribonucleo-
proteins A2/B1 in cluster 2 showed an opposite trend to
calreticulin (Figure 2C).
OT suppressed phosphoprotein expression in MIA PaCa-2
cells
Particularly, reversible phosphorylation of proteins plays a
significant role that occurs in both prokaryotic and
eukaryotic organisms, including cell apoptosis and differen-
tiation, signal transduction, cell-cycle progression, energy
storage and utilization [30-33]. To study whether cellularphosphor proteins were also altered by OT treatment,
we analyzed phosphor protein expression in MIA cells
(Figure 3). Obviously, OT suppressed expression of cellular
phosphor proteins significantly. A total of 14 phosphory-
lated proteins were identified (Figure 3), and listed in
Table 2. Of these 14 phosphorylated proteins, 6 proteins in
Cluster 1 (heat shock cognate 71 kDa protein, 14-3-3 pro-
tein epsilon, 14-3-3 protein beta/alpha, 14-3-3 protein zeta/
delta, eukaryotic translation initiation factor 6 and gluta-
thione S-transferase P) showed concordant changes with
total proteins, 6 proteins of Clusters 2 and 3 (nuclear
autoantigenic sperm protein, stress-induced-phosphopro-
tein 1, alpha-enolase, eukaryotic translation initiation factor
3 subunit I, F-actin-capping protein subunit alpha-2 and
tumor necrosis factor ligand superfamily member 13B)
were discordant, and 2 (loss of heterozygosity 12 chromo-
somal region 1 protein and eukaryotic translation initiation
factor 5A-1) were only observed in the phosphorylated
patterns (Figure 3, Table 2). Decrease in phosphorylated
proteins induced by OT treatment indicated that the inhib-
ition of pentose phosphate pathway might cause a time-
dependent decrease of phosphorylated proteins patterns.
Functional annotation of the differential proteins identified
To annotate the proteins identified in this study, all 52 dif-
ferential proteins were analyzed with Ingenuity Pathway
Figure 2 Time-dependent analysis of the MIA PaCa-2 cells to oxythiamine. A. Two-DE patterns of total proteins from the MIA PaCa-2 cells
treated by OT with 0, 12 and 48 h. On the basis of PDQuest software analysis, ratios of normalized spot intensities of four different concentrations
of oxythiamine were calculated, and spots showing more than 2.0-fold difference with statistical significance (p < 0.05) were selected after these
2D gels were stained with SYPRO Ruby. B. The temporal profile patterns of 45 differential proteins. The 0 min value was used as a basal time
point to calculate the protein fold changes in 12 h and 48 h. After transformed to the logarithmic scale (base 2), the temporal changed profiles
of 45 differentially proteins were algorithmically subdivided into nine clusters using K-means clustering method. The protein number of each
cluster is indicated. C. The validation of four differential proteins (peroxiredoxin-6, annexin A1, calreticulin and heterogeneous nuclear
ribonucleoproteins A2/B1) for the time-dependent group. Western blot scores are annotated under the bands. The results were well consistent
with the 2-DE analyses.
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tional annotation of these proteins revealed that most of
the proteins were involved in signaling transduction of cell
death, including cell death signaling (29, 37.7%), gene ex-
pression (12, 15.6%), post-translational modification (14,
18.2%), cell-to-cell interaction (11, 14.3%), protein folding
(5, 6.5%), and protein trafficking (6, 7.8%) (Figure 4A).
Moreover, many proteins were involved in multiple signal-
ing pathways that play role in incidence of diseases, in-
cluding cancer (28, 24.3%), reproductive system disease
(17, 14.8%), gastrointestinal disease (12, 10.4%), hemato-
logical disease (12, 10.4%), immunological disease (16,
13.9%), inflammatory disease (19, 16.5%), respiratory dis-
ease (11, 9.6%) (Figure 4B).
The proteins quantitatively measured with turnover rate
(a total of 36 proteins) were also annotated using IPA bio-
informatics (Figure 4C). The differentially expressed proteins
in three clusters are involved in multiple signaling pathwaysthat are associated with tumor cell survival, and apoptosis.
For examples, 14-3-3 proteins (14-3-3 protein epsilon, 14-3-
3 protein beta/alpha and 14-3-3 protein zeta/delta) in cluster
1, play roles in cell survival, cell proliferation, anti-apoptosis
and anti-tumor suppression by activating ERK/MAPK sig-
naling pathway and the mitochondrial apoptotic machinery
[34-37]. Peroxiredoxin-2 and peroxiredoxin-4 in cluster 2,
which were up-regulated in many cancers [38-40], showed a
significant decrease upon OT-treatment for 12 hr but in-
creased to almost basal level after OT treatment for 48 hr. It
suggested that these proteins in cluster 2 might be the early
response molecules upon OT-treatment. Calreticulin in
cluster 3, which is associated with proimmunogenic killing
in cancer cells [41], was up-regulated upon OT-treatment
for 12 hr but then down-regulated to almost basal level
after treatment for 48 hr, suggesting that OT-induced cell
apoptosis might be associated with proimmunogenic kill-
ing in the early time.
Table 2 Identified proteins of differential expression of the MIA PaCa-2 cells in the OT-time dependent group by
MALDI-TOF/TOF MS
Spot No.a Accession numberb Protein name
Ratio of OT-induced differential expressionc
Total proteins Phosphorylated proteins
0 24 48 (h) 0 24 48 (h)
1 P49321e Nuclear autoantigenic sperm protein 1.00 0.37 1.35 1.00 0.09 0.05
2 P14625f Endoplasmin 1.00 1.17 0.26 – – –
3 Q14697 e Neutral alpha-glucosidase AB 1.00 0.41 0.89 – – –
4 P11142d Heat shock cognate 71 kDa protein 1.00 0.62 0.45 1.00 0.13 0.08
5 P29401 f Transketolase 1.00 3.23 0.77 – – –
6 P31948 d Stress-induced-phosphoprotein 1 1.00 0.61 0.28 1.00 1.17 0.19
7 P30101 d Protein disulfide-isomerase A3 1.00 0.30 0.06 – – –
8 P17987 d T-complex protein 1 subunit alpha 1.00 0.39 0.21 – – –
9 P31146 e Coronin-1A 1.00 0.45 0.74 – – –
10 P31943 d Heterogeneous nuclear ribonucleoprotein H 1.00 0.88 0.49 – – –
11 P07237 e Protein disulfide-isomerase 1.00 0.37 0.84 – – –
12 P13489 d Ribonuclease inhibitor 1.00 0.91 0.23 – – –
13 P27797 f Calreticulin 1.00 3.58 0.95 – – –
14 P06733 f Alpha-enolase 1.00 2.37 0.82 1.00 0.24 0.07
15 Q86VC0 f 40S ribosomal protein SA 1.00 1.35 2.00 – – –
16 P52597 e Heterogeneous nuclear ribonucleoprotein F 1.00 0.31 0.73 – – –
17 P52907 e F-actin-capping protein subunit alpha-1 1.00 0.49 0.81 – – –
18 O75821 e Eukaryotic translation initiation factor 3 subunit I 1.00 0.29 0.72 1.00 0.73 0.29
19 P47755 e F-actin-capping protein subunit alpha-2 1.00 0.43 0.87 1.00 0.20 0.03
20 P04083 d Annexin A1 1.00 0.87 0.48 – – –
21 P04406 e Glyceraldehyde-3-phosphate dehydrogenase 1.00 0.39 1.25 – – –
22 P04406 e Glyceraldehyde-3-phosphate dehydrogenase 1.00 0.41 1.32 – – –
23 P09651 e Heterogeneous nuclear ribonucleoprotein A1 1.00 0.17 1.39 – – –
24 P22626 e Heterogeneous nuclear ribonucleoproteins A2/B1 1.00 0.06 0.33 – – –
25 P52895 e Aldo-keto reductase family 1 member C2 1.00 0.48 4.02 – – –
26 Q9BYE2 d Serine/threonine-protein kinase 13 1.00 0.11 0.07 – – –
27 P08758 d Annexin A5 1.00 0.43 0.36 – – –
28 Q9Y275 d 14-3-3 protein epsilon 1.00 0.34 0.12 1.00 0.36 0.15
29 P31946 d 14-3-3 protein beta/alpha 1.00 0.39 0.22 1.00 0.31 0.74
30 P63104 d 14-3-3 protein zeta/delta 1.00 0.42 0.28 1.00 0.87 0.14
31 P56537 e Eukaryotic translation initiation factor 6 1.00 0.39 0.47 1.00 0.76 0.41
32 P62258 f Tumor necrosis factor ligand superfamily member 13B 1.00 2.13 0.29 1.00 0.33 0.17
33 Q6ZU15 e Septin-14 1.00 0.04 0.78 – – –
34 Q13162 e Peroxiredoxin-4 1.00 0.20 0.53 – – –
35 P18669 e Phosphoglycerate mutase 1 1.00 0.08 2.59 – – –
36 P63244 e Guanine nucleotide-binding protein subunit beta-2-like 1 1.00 0.49 0.91 – – –
37 P04792 d Heat shock protein beta-1 1.00 0.43 0.28 – – –
38 P30041 d Peroxiredoxin-6 1.00 0.89 0.37 – – –
39 P09211 d Glutathione S-transferase P 1.00 0.77 0.42 1.00 0.26 0.04
40 P16949 e Stathmin 1.00 0.35 0.46 – – –
41 P15531 d Nucleoside diphosphate kinase A 1.00 0.97 0.09 – – –
42 P32119 e Peroxiredoxin-2 1.00 0.37 0.49 – – –
43 P60660 d Myosin light polypeptide 6 1.00 0.88 0.23 – – –
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Table 2 Identified proteins of differential expression of the MIA PaCa-2 cells in the OT-time dependent group by
MALDI-TOF/TOF MS (Continued)
44 Q8N1F1f Putative uncharacterized protein NCRNA00188 1.00 1.15 0.50 – – –
45 P05109 e Protein S100-A8 1.00 0.29 0.73 – – –
46 P62937 e Peptidyl-prolyl cis-trans isomerase A 1.00 0.07 0.19 – – –
47 Q969J3 Loss of heterozygosity 12 chromosomal region 1 protein – – – 1.00 0.13 0.02
48 P63241 Eukaryotic translation initiation factor 5A-1 – – – 1.00 0.14 0.05
a. The numbers of the identified protein spots are indicated in Figures 1, 2, and 3;
b. Swiss-Prot/TrEMBL primary accession number.
c. The ratio of expression level (intensity on the gel) of each protein spot were calculated based on the control (0 μM OT) group.
d. Protein expression in Cluster 1.
e. Protein expression in Cluster 2.
f. Protein expression in Cluster 3.
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Dynamic protein synthesis, which is the results of pro-
tein synthesis and degradation, is the key to regulate the
cell signaling and determine the cell destiny [42,43]. In our
study, dynamic protein synthesis rates of differential pro-
teins were able to be determined by our recently developed
method [24]. A total of 41 proteins were measured, inclu-
ding 7 proteins with a turnover rate < 45% (protein
disulfide-isomerase A3, alpha-enolase, tumor necrosis fac-
tor ligand superfamily member 13B, eukaryotic translation
initiation factor 6, nucleoside diphosphate kinase A, my-
osin light polypeptide 6 and phosphoglycerate mutase 1), 5
proteins with a turnover rate > 65% (heterogeneous nuclear
ribonucleoproteins A2/B1, peroxiredoxin-2, peroxiredoxin-
6, endoplasmin and nuclear autoantigenic sperm protein)
and other 29 proteins with a turnover rate between 45%
and 65% (Table 3). Proteins with high protein turnover rate
indicated they may be actively involved in some cell
physiological processes, especially in drug treatment cells.
We also examined the time-dependent relationship of
protein synthesis to OT treatment in MIA PaCa cells
(Table 3). Because of the low protein concentration re-
covered from the 2-D gel, we were only able to deter-
mine the fraction of new synthesis in eight proteins at
the various time points of OT treatment. Table 3 shows
the time response of the fraction of new synthesis (%Figure 3 Two-DE patterns of phosphorylated proteins from the MIA Pnew synthesis in 12 and 48 hours) of eight proteins.
There were no significant mass shifts of the peptide
spectra at 12 h time point of OT treatment. It indicated
that there may be no the new syntheses of proteins be-
fore 12 h. Fraction of new syntheses of five proteins were
decreased, three were increased at 48 h time point of
OT treatment. It suggested the differential effects of OT
treatment on protein turnover of the eight proteins.
The effect of 15 N incorporation on the isotopomer
distribution of a peptide from protein spot #20 is illus-
trated in Figure 5. The isotopomer distribution of frag-
ment 1702.5 m/z in spot #20 (Annexin A1) is shown in
Figure 5A-F. The distribution of the unlabeled fragment
(14 N) is showed in Figure 5A.
The same peptide, labeled with 15 N enriched medium
and treated with or without 50 μM OT for 12 h, is illus-
trated in Figure 5B,C. There were no significant differ-
ences between the three spectra. It indicated protein
synthesis was not interrupted at the 12 h time point of
OT treatment in the MIA PaCa-2 cells. Figure 5D shows
the spectrum from cells grown in 50% 15 N enriched
medium for 48 h. It suggested the obvious spectrum
shift in mass comparing with 14 N labeled spectrum. The
spectrum in Figure 5E is from the cells grown in 15 N
enriched medium and 50 μM OT for 48 h, which
showed smaller mass shift than that of only 50% 15 NaCa-2 cells treated by OT with 0, 12 and 48 h.
Figure 4 Functional characteristics of the differential proteins identified. A. Functional analysis of fifty-two differential proteins via Ingenuity
database (www.ingenuity.com). Molecular functional annotation including cell death (29, 37.7%), gene expression (12, 15.6%), post-translational
modification (14, 18.2%), cell-to-cell signaling and interaction (11, 14.3%), protein folding (5, 6.5%), protein trafficking (6, 7.8%). B. Classification
related with diseases and disorders including cancer (28, 24.3%), reproductive system disease (17, 14.8%), gastrointestinal disease (12, 10.4%),
hematological disease (12, 10.4%), immunological disease (16, 13.9%), inflammatory disease (19, 16.5%), respiratory disease (11, 9.6%). C. The
analysis of network based on the Ingenuity database. A total of 36 differential proteins, which showed three different profiles response to OT
treatment, were matched in the signaling network of cancer and cell death.
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multiple linear regression analysis of the observed pep-
tide spectrum. The fraction of new synthesis of the pep-
tide was reduced from 55% to 37% by OT treatment.
Using a Mascot database search, we determined that the
sequence of the peptide is part of a protein annexin A1Table 3 OT interrupted the protein synthesis rates
Protein name 48
Endoplasmin




Heterogeneous nuclear ribonucleoprotein F
Heterogeneous nuclear ribonucleoproteins A2/B1
Peroxiredoxin-4
Peroxiredoxin-6
g. Protein turnover rates were measured from cells treated with 15 N enriched med
h. Protein turnover rates were measured from cells treated with 15 N enriched med
i. Protein turnover rates were measured from cells treated with 15 N enriched mediu
j. “–” means no significant changes of protein turnover rates compare to basal grou(Figure 5F). It suggested that OT could inhibit the syn-
thesis of annexin A1.
Expression of Annexin A1 in human pancreatic cancer
Annexin A1, a major substrate for epidermal growth fac-
tor receptor kinase, plays an important role in cancerProtein synthesis rate











ium for 48 h without OT treatment.
ium and 50 μM OT for 12 h.
m and 50 μM OT for 48 h.
p (0 hr).
Figure 5 OT interrupted protein synthesis rate of annexin A1. MS spectra of 1702.5 m/z fragment from spot #20 of lysates of cells grown in
the presence of natural amino acids (A), 50% 15 N enriched medium and 0 μM OT for 12 h (B) and 50% 15 N enriched medium and 50 μM OT for
12 h (C), 50% 15 N enriched medium and 0 μM OT for 48 h (D), 15 N enriched medium and 50 μM OT for 48 h (E). The synthesis rate of a protein
was based on the isotopomer distribution of these spectra. (F). shows the MS/MS spectrum of this fragment in the “lift” mode. Sequences were
confirmed from the labeled b- and y-ions in the spectrum using a Mascot database search.
Figure 6 Differantial expression of annexin A1 in pancreatic
cancer and healthy plasma. A. Western blot of seven random
pairs of human plasma from pancreatic cancer and healthy people.
B. Statistical analysis of the Western blot in the Panel A. Band
intensity was normalized to that of tubulin. C, plasma from
pancreatic cancer patiant; H, palsma from healthy people.
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sion of Annexin A1 was reported to be associated with a
number of cancers including pancreatic cancer [46], the
molecular mechanism underlying is unknown. To fur-
ther validate the expression of Annexin A1 in patients
with pancreatic cancer, Western blot analysis was
performed in archived clinic plasma samples from pa-
tients who had pancreatic cancer (n = 7) and healthy
control (n = 7) (Figure 6A/B). Clearly, Annexin A1 is
expressed significantly in pancreatic cancer patients
compared to the healthy controls (p < 0.05) (Figure 6B).
These results agreed well with our in vitro study above,
suggesting that Annexin A1 may be developed as a sur-
rogated marker potentially useful for early detection of
pancreatic cancer.
Discussion
Cancer cells utilize glucose maximally as a main source of
energy supply and substrates for proliferation through
glycolytic metabolic pathways [1,2]. Inhibition of the activ-
ity of the key enzymes (e.g., transketolase/transadolase) in
these metabolic networks, resulting in significant limita-
tion of glucose utilization, provides an ideal strategy for an
effective therapy of cancer. A number of our previous
studies have shown that inhibition of activity of either
transketolase in the pentose phosphate cycle, or glycogen
phosphorylase causes cell cycle arrest leading to cancer
cell apoptosis [17,23,47,48]. In this study, we found thattransketolase inhibitor OT altered dynamics of cellular
protein expression in MIA PaCa-2 cells by interrupting
the rates of protein de novo synthesis. This study provides
1) an important clinical implication for identifying novel
cellular protein signals/targets that are associated
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proach for detecting signal molecules that initiate drug
resistance.
Small molecule antimetabolites are among the more
effective chemotherapeutic agents in use today. Cur-
rently, gemcitabine, 5-fluorouracil (5-FU), and imatinib,
are commonly used for the treatment of pancreatic can-
cer [49-51]. However, the response rate to either
gemcitabine, or imatinib, and patient survival, are poor
[52,53]. There is an urgent need to discover additional
chemotherapeutic targets such as metabolic enzymes that
play a crucial role in controlling the growth of cancer cells.
In this study, we found that OT caused protein expression
in a time dependent fashion. Peroxiredoxin-6 of cluster 1,
which can suppress TRAIL-mediated cell death in human
cancer cells by binding to death effector domain caspase
[54], was constantly down-regulated by the duration of
OT treatment (from 0 hr to 48 hrs) (Figure 2B). It impli-
cated that OT induced cell death by hperoxiredoxin-6 re-
lated TRAIL-induced pathway. However, peroxiredoxin-2
and peroxiredoxin-4 of cluster 2, the same ubiquitous
family of peroxiredoxin-6, which were up-regulated in
many cancers [38-40], were shown in an upright “V” shape
(Figure 2B). It suggested that the two proteins might be
the only early response molecules upon OT-treatment
comparing with peroxiredoxin-6. Calreticulin of cluster 3
was shown in a downright “V” shape (Figure 2B). It
suggested calreticulin might have an opposite function of OT-
induced cell apoptosis as the early time response molecu-
lar comparing with peroxiredoxin-2 and peroxiredoxin-4.
The protein expression pattern in three clusters suggested
that metabolic dynamic changes (dynamic changes of
transketolase activity) in MIA cancer cells in response to
OT treatment caused dynamic changes of cellular protein
signals. Protein expression pattern indicates that dynamics
of these protein expressions differs in MIA cells in re-
sponse to OT treatment. Interestingly, expression of these
proteins in cluster 2 and 3 was no significant difference in
MIA cells treated with OT for 48 hrs, but significantly
changed in MIA cells treated with OT for 12 hrs, com-
pared to that in MIA cells at basal line (0 hrs). Early
response proteins (e.g., Glyceraldehyde-3-phosphate dehy-
drogenase, S100A8) in clusters 2 and 3 may play an
important role in MIA cells against OT treatment. Several
studies revealed that expression of both Glyceraldehyde-3-
phosphate dehydrogenase and S100A8 are suppressed in
Raw264.7 cells [25,26,55]or bone cells [56,57] in response
to toxins or tobacco smoke, suggesting that these proteins
play an important role in cell defense (survival). Suppres-
sion of the protein expression may be part of cell emergent
response mechanism since OT treatment cut off supplies
of substrates and energy for cancer cell proliferation.
Because of a wild range of protein concentration in
cells, it is the most difficult to study in a trulycomprehensive manner. Standard proteomics usually
compares amounts of proteins in cells in two different
states (e.g. disease vs. normal) or conditions (e.g. treat-
ment vs. non treatment) [58]; it does not address the dy-
namics of the proteome in the different biological states
that are being compared, nor does it provide information
about the mechanisms whereby the system changes from
one state to the other. Thus, data obtained from this
study may provide unique cell survival mechanism.
Previous study showed that dynamic changes of meta-
bolic enzyme activity determined the metabolic sensitiv-
ity of cancer cells to the treatment [47], therefore, the
early responsive protein signals upon OT treatment may
be indicatives for the sensitivity of pancreatic cancer
cells to the treatment in molecular level.
The dynamic changes of the cellular molecules
(mRNAs, proteins, and metabolites) depend upon the
physiological, developmental, or pathological state of liv-
ing cells [59]. A change in the proteome may be the
most important outcomes of a cellular response, such as
autophagy, to exogenous stimuli. Autophagy is a consti-
tutive, catabolic process leading to the lysosomal degrad-
ation of cytosolic proteins and organelles. Dynamic
changes of proteins identified in Clusters 3 and 4 may
reflect the cellular autophaging phenomena.
Because of a wild range of protein concentration in cells,
it is the most difficult to study changes of protein expres-
sion in a truly comprehensive manner. Standard proteo-
mics usually compares amounts of proteins in cells in two
different states (e.g. disease vs. normal) or conditions (e.g.
treatment vs. non treatment) [58]; it does not address the
dynamics of the proteome in the different biological states
that are being compared, nor does it provide information
about the mechanisms whereby the system changes from
one state to the other. This study provides more dynamic
information of cellular protein signals than our previous
studies and others [23], which some dynamic information
of proteins in clusters 2 and 3 may be missed (or so-called
“false negative” errors) when standard proteomics ap-
proach is used in our previous studies.
Protein turnover is the balance between protein syn-
thesis and protein degradation (or breakdown), which is
believed to decrease with age in all senescence organ-
isms including humans. This results in an increase in
the amount of damaged protein within the body. It is
unknown if this is a cause or consequence of aging but
it seems likely that it is in fact both. The damaged pro-
tein results in a slower protein turnover which then re-
sults in more damaged protein causing an exponential
increase in damage to all protein within the body and to
aging. Protein turnover is being considered as a missing
dimension in proteomics for biomedical research [59].
The dynamics of protein turnover is one of key features
to the understanding of regulation of protein expression
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of expression of a protein depends on the rates of its
synthesis and degradation. Thus the turnover of a pro-
tein is an important indicator of its functional signifi-
cance in cells. Despite its evident importance, the role of
protein turnover has not previously been considered in
analyses of the proteome. Protein turnover can be quanti-
fied on a protein-by-protein basis. With the established
method [24], in this study we were able to quantitatively
measure the rates of newly synthesized proteins. Among
41 proteins measured, 7 proteins are with a turnover rate
of < 45%, 5 proteins are with a turnover rate of > 65%, and
29 proteins are with a turnover rate between 45% and
65%. The turnover rates of the proteins with extreme high
or low levels are related to specific status of cell physiology
(e.g., suppression of metabolic signaling).
Intriguingly, we did not observe de novo synthesized
peptides in MIA cells treated with OT in 12 h. This is
reasonable since it takes more than 24 hr for a specific
gene translating to the cognate protein. The explanation
for detection of the differential expressed proteins at
12-h treatment may be 1) because OT directly or indir-
ectly activated pathways of degradation resulting in
rapid degradation of cellular functional proteins; 2) be-
cause OT directly or indirectly turned on pathways of
posttranslational modification leading to the increased
amount of proteins. This notion can be demonstrated
from Figure 6B/C, obviously, de novo synthesis of pro-
teins cannot be detected.
Previous study revealed that some active metabolic
pathways, TCA, glycolysis, oxidative phosphorylation and
the pentose phosphate pathway, were interconnected with
the critical signaling pathways in proliferating cells [61].
Inhibiting of these metabolic pathways could affect the
biological macromolecular synthesis and suppress cell
proliferation [23,47]. In previous studies it had been
shown OT could cause the inhibition of nucleic acid syn-
thesis metabolic through increasing imbalances in pentose
phosphate cycle [18]. In our study, the expression profile
patterns of cellular phosphorylated proteins of MIA PaCa-
2 were significantly inhibited by OT treatment (Figure 3).
This phenomenon might be caused by inhibition of bio-
logical macromolecular synthesis or some critical signaling
pathways related phosphorylation.
Certainly, this is a principal proof study examining
whether interference of the interactive metabolic and
cell signaling pathways alters expression of protein sig-
nals associated with cellular abnormal activity of protein
turnover. Although information obtained in a single
pancreatic cancer cell line MIA PaCa-2 may be limited
to a study in other cell lines, protein signals identified in
this study may provide useful information for further de-
velopment of novel biomarkers and/or drug targets for
administration of pancreatic cancer.Conclusion
This study revealed that inhibition of single metabolic
enzyme transketolase by OT altered dynamics of cellular
protein expression by interfering rates of de novo protein
synthesis in MIA PaCa-2 pancreatic cancer cells. These
cellular dynamic protein signals may be involved in sev-
eral signaling pathways of cell apoptosis. These results
may help understand better molecular mechanism of the
anti-tumor activity of OT.
Additional file
Additional file 1: Figure S1. The effects of OT on MIA PaCa-2-2 cell
proliferation using MTT assay. OT could cause the inhibition of cell growth
and induce cell apoptosis on MIA PaCa-2 cell in a dose-dependent manner.
IC50 of OT for MIA PaCa-2-2 cells was 14.95 μM.
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